论文部分内容阅读
米卡芬净(micafungin,FK463,商品名 Mycamine,由日本藤泽公司研制开发)2002年首次在日本上市,主要用于治疗曲霉菌属和念珠菌属所致的感染,并于2006年得到儿童适应证的批复。它是2005年美国 FDA 批准上市的第二个棘白菌素类抗真菌药,2006年也已在中国批准上市,对包括对唑类药物耐药的念珠菌属和曲霉菌属具有广谱的抗菌活性,动物实验和临床试验表明其耐受性良好,疗效确切。米
Micafungin (FK463, trade name Mycamine, developed by Fujisawa Japan Inc.) was first marketed in Japan in 2002. It is mainly used for the treatment of infections caused by Aspergillus and Candida and was acquired in 2006 by children Reply to the indication. It is the second echinocandin antifungal agent approved by the FDA in 2005 and has also been approved for marketing in China in 2006. It has a broad spectrum of resistance to Candida and Aspergillus including azole drugs Antibacterial activity, animal experiments and clinical trials show that the well tolerated, curative effect. Meter